TRI-JORDYNA 21 0.035 MG — DIN 02486296
ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.18 MG ETHINYL ESTRADIOL : 0.035 MG ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.215 MG NORGESTIMATE : 0.25 MG · GLENMARK PHARMACEUTICALS CANADA INC. · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is TRI-JORDYNA 21?
TRI-JORDYNA 21 0.035 MG contains ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.18 MG ETHINYL ESTRADIOL : 0.035 MG ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.215 MG NORGESTIMATE : 0.25 MG. It is listed in the Health Canada Drug Product Database under DIN 02486296, held by GLENMARK PHARMACEUTICALS CANADA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 08-Jul-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Is there a generic Norgestimate And Ethinylestradiol in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Norgestimate And Ethinylestradiol, across 6 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 4 | 4 | TRI-CIRA 21, TRI-CIRA 28, TRI-CIRA LO 21, TRI-CIRA LO 28 | Sourceable in Canada |
| GLENMARK PHARMACEUTICALS CANADA INC. | 2 | 2 | TRI-JORDYNA 21, TRI-JORDYNA 28 | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.035 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Norgestimate And Ethinylestradiol |
|---|---|
| ATC code | G03AB09 |
| AHFS class | 68:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02486296 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2486296 |
| Brand name | TRI-JORDYNA 21 |
| Generic / active ingredient | ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.18 MG ETHINYL ESTRADIOL : 0.035 MG ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.215 MG NORGESTIMATE : 0.25 MG |
| Market authorization holder | GLENMARK PHARMACEUTICALS CANADA INC. |
| Health Canada schedule | Prescription |
| ATC code | G03AB09 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03AB |
| Current status | MARKETED |
| Status date | 08-Jul-2020 |
| Original market date | 2020-07-08 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 6 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| TRI-CIRA 21 | 0.035 MG | TABLET | APOTEX INC | MARKETED | 02508087 |
| TRI-CIRA 28 | 0.215 MG | TABLET | APOTEX INC | MARKETED | 02508095 |
| TRI-CIRA LO 21 | 0.025 MG | TABLET | APOTEX INC | MARKETED | 02401967 |
| TRI-CIRA LO 28 | 0.025 MG | TABLET | APOTEX INC | MARKETED | 02401975 |
| TRI-JORDYNA 28 | 0.25 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | 02486318 |
2 · Same class — other molecules in ATC G03AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Norgestimate And Ethinylestradiol | TRI-CIRA 21 · TRI-CIRA 28 · TRI-CIRA LO 21 · TRI-CIRA LO 28 · +2 more | 6 | 6 | Yes |
| Norethisterone And Estrogen | LOLO · ORTHO 10/11 TABLETS (21 DAY) · ORTHO 10/11 TABLETS (28 DAY) · ORTHO 7/7/7 TABLETS (21 DAY) · +4 more | 9 | 3 | Yes |
| Levonorgestrel And Estrogen | QUATERNA · SEASONIQUE · TRIPHASIL 21 · TRIPHASIL 21 TAB · +4 more | 8 | 3 | Yes |
| Desogestrel And Estrogen | LINESSA 21 · LINESSA 28 | 2 | 2 | Yes |
| Norgestimate And Estrogen | CENTRISA 21 · CENTRISA 28 · CENTRISA LO 21 · CENTRISA LO 28 · +8 more | 12 | 0 | Not in Canada |
| Progestogens And Estrogens, Sequential Preparations | TRI-PREVIFEM (21 DAY) · TRI-PREVIFEM (28 DAY) | 2 | 0 | Not in Canada |
| Dienogest And Estrogen | NATAZIA | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G03AA | Desogestrel And Estrogen · Drospirenone And Estetrol · Drospirenone And Estrogen · Etynodiol And Estrogen · Levonorgestrel And Estrogen · +4 more | 105 | 46 |
| G03AC | Drospirenone · Etonogestrel · Levonorgestrel · Medroxyprogesterone · Norethisterone · +1 more | 13 | 6 |
| G03AD | Levonorgestrel · Ulipristal | 14 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.